Breast cancer; prostate cancer; endometriosis; endometrial thinning prior to endometrial ablation.
3.6mg depot S.C into the anterior abdominal wall every 28 days. 6 months only for endometriosis.
Mode of action
Brands containing this Ingredient
Drug Index 2.0 is hereOur new update features a more powerful search feature and easier login.
issues? Contact us
today. Contact Us
Mode of Action
It is a synthetic decapeptide analogue of luteinizing hormone-releasing hormone [gonadotropin releasing hormone, GnRH, agonist analogue]. Its initial administration stimulates release of gonadotropins, LH and FSH, from the anterior pituitary. This is followed by their suppression.
Lactation; undiagnosed abnormal uterine bleeding; patients with ureteral obstruction or spinal cord compression should have appropriate treatment prior to initiation of therapy in male patients.
Pregnancy; sensitivity to goserelin and related compounds.
Most of side effects are related to hypoestrogenism in females and hypotestosteronism in males. loss of vertebral trabecular bone density in female; cardiac arrhythmias or palpitations; anaphylaxis; bone, muscle, or joint pain; paresthesias; syncope; androgenic effects; personality or behavioral changes; angina; myocardial infarction; pulmonary embolism; thrombophlebitis; amenorrhea; spotting; blurred vision; decreased libido; dizziness; oedema; headache; injection site reaction; nausea or vomiting; swelling or increased tenderness of breasts; trouble in sleeping; weight gain; transient endometriotic disease flare; vaginitis; constipation in male; decreased size of testicles; impotence in male; transient prostates carcinoma disease flare.